Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Inc. AMGN, -0.37% announced Thursday a research collaboration with privately held Generate Biomedicines to discover and create protein therapeutics, which could lead to a potential payment to Generate by Amgen of $1.9 billion. Under terms of the agreement, which is initially for five clinical target programs, Amgen said it will provide $50 million in upfront funding and will pay up to $370 million in future milestones and royalties for each program.

Amgen could pay Generate Biomedicines up to $1.9 billion as part of research collaboration agreement

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass.

AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT

Bristol-Myers

Gilead Sciences

Eli Lilly

Novocure

United Therapeutics

SPDR S&P Pharmaceuticals ETF

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

7 Pharmaceutical Stocks That Could Make You Rich

Boeing

Disney

Dow Inc

Honeywell

Merck

Visa

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walmart

"There are a few comeback stories in the dogs of the Dow, but for the most part I don't expect these dogs to have their day in 2022," the "Mad Money" host said.

Jim Cramer's 2022 forecast for3M

Best Buy

Franklin Resources

Lockheed Martin

Morgan Stanley

M&T Bank

Philip Morris

Toronto-Dominion Bank

ViacomCBS

I present my top 10 High Yield dividend stocks that are poised to offer strong future returns. The annualized rate of return for this watchlist is 39.18% over the past 14 months.

My Top 10 High Yield Dividend Stocks For January 2022

Amgen Inc. AMGN, +0.03% was downgraded at BofA Securities, with analyst Geoff Meacham saying he believes the lingering COVID-19 headwinds and net pricing pressures that weighed on the biotechnology company in 2021 are likely to continue this year. Meacham cut his rating to neutral, after being at buy since March 2020, and lowered his stock price target to $255 from $285.

Amgen downgraded at COVID-19, pricing headwinds could push out growth inflection to next year

The U.S. Food and Drug Administration recently approved Amgen's Otezla to treat all severity levels of plaque psoriasis.

What Does This Label Expansion Mean for Amgen's Shareholders?

Chevron

Intel

Coca-Cola

Walgreens

The decades-old income-and-value strategy, the Dogs of the Dow, will try to bounce back in 2022. Here are this year's 10 members.

Dogs of the Dow 2022: 10 Dividend Stocks to Watch

ABM Industries

Abbott Labs

American Tower

Alexandria Real Estate Equities

AvalonBay Communities

Broadcom

Axis Capital

Baxter

Balchem

Flanigan's Enterprises

Camden National

C.H. Robinson Worldwide

Culp

Calavo Growers

Ecolab

EastGroup Properties

Edison

Eastman Chemical

Ensign Group

Monthly update of the Dividend Champions List. 54 companies declared higher dividends in the past month, with an average increase of 8.71% over their previous payouts.

Dividend Champions For January 2022

Cisco Systems

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2022 Dogs of the Dow

American Electric Power Company

Allstate

Air Products and Chemicals

Bank of New York Mellon

Comcast

JPMorgan Chase & Co

L3Harris

PACCAR

Snap-on

T. Rowe Price Group

Texas Instruments

U.S. Bancorp

Using five stringent stock selection criteria and two additional screens, I found sixteen dividend growth stocks suitable for further research and possible investment in 2022. The criteria consider Stock Quality, Stock Valuation, Growth Outlook, Income Outlook, and Dividend Safety. I also screen by dividend increase streak and using a popular performance metric.

My Top 16 Dividend Growth Stock Picks For 2022

I list my 3 top-quality dividend growth stocks for 2022. The reasons why these stocks may be attractive to investors in 2022 are examined closely. I discuss the dividend safety and valuation of all three dividend growth stocks.

Top 3 Dividend Growth Stocks For 2022

CVS Health

All three companies rewarded shareholders with significant payout increases.

These 3 Stocks Just Hiked Their Dividends: Should You Buy Them?

In 2019, the Dow Jones industrial average rose by 22.34%. In 2020, the COVID-19 pandemic cut that growth spurt by two-thirds, for a gain of just 7.25%.

2022's Dogs of the Dow

Apple

American Express

Goldman Sachs

Procter & Gamble

UnitedHealth Group

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." Thirty-one Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated net-gains ranged 14.16%-28.38% topped by BA 12/29/21.

January Dogs Of The Dow Need A Pullback

AbbVie

BlackRock Taxable Municipal Bond Trust

No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited drawdowns in case of deep corrections.

The Near-Perfect Portfolio For The Bull Markets And The Bear Markets

News for Amgen Stock (AMGN)